Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5284) 5284
life sciences & biomedicine (5030) 5030
animals (3757) 3757
staurosporine - pharmacology (3497) 3497
humans (3311) 3311
staurosporine (3253) 3253
biological and medical sciences (2365) 2365
protein kinase c - antagonists & inhibitors (2039) 2039
alkaloids - pharmacology (2020) 2020
enzyme inhibitors - pharmacology (1944) 1944
biochemistry & molecular biology (1758) 1758
apoptosis (1551) 1551
fundamental and applied biological sciences. psychology (1509) 1509
rats (1490) 1490
cell biology (1334) 1334
cells, cultured (1274) 1274
apoptosis - drug effects (1245) 1245
tetradecanoylphorbol acetate - pharmacology (1188) 1188
mice (1137) 1137
protein kinase c - metabolism (1110) 1110
male (1004) 1004
phosphorylation (928) 928
medical sciences (917) 917
cell line (870) 870
protein kinase c (775) 775
oncology (708) 708
dose-response relationship, drug (698) 698
tumor cells, cultured (689) 689
female (685) 685
kinetics (678) 678
signal transduction (672) 672
staurosporine - analogs & derivatives (658) 658
molecular and cellular biology (623) 623
calcium - metabolism (612) 612
neurosciences (594) 594
neurosciences & neurology (580) 580
pharmacology & pharmacy (574) 574
enzyme activation (571) 571
in vitro techniques (538) 538
time factors (516) 516
apoptosis - physiology (514) 514
cell line, tumor (484) 484
caspases - metabolism (476) 476
cell physiology (467) 467
pharmacology. drug treatments (456) 456
proteins (441) 441
isoquinolines - pharmacology (429) 429
enzyme activation - drug effects (416) 416
protein kinase inhibitors (415) 415
research article (414) 414
protein kinase c - physiology (412) 412
transfection (407) 407
signal transduction - drug effects (395) 395
biophysics (385) 385
molecular sequence data (375) 375
physiology (371) 371
rats, sprague-dawley (365) 365
blotting, western (362) 362
piperazines - pharmacology (354) 354
abridged index medicus (338) 338
cell survival - drug effects (337) 337
antineoplastic agents - pharmacology (331) 331
1--2-methylpiperazine (324) 324
research (321) 321
indoles - pharmacology (305) 305
cell death (302) 302
neurons - drug effects (300) 300
immunology (297) 297
amino acid sequence (290) 290
mutation (289) 289
caspase 3 (287) 287
protein kinases (285) 285
antineoplastic agents (277) 277
kinases (277) 277
analysis (271) 271
hela cells (267) 267
gene expression (258) 258
physiological aspects (258) 258
protein kinase inhibitors - pharmacology (255) 255
flow cytometry (254) 254
hematology (251) 251
phosphorylation - drug effects (250) 250
protein kinases - metabolism (248) 248
rats, wistar (248) 248
cell division - drug effects (243) 243
mitochondria - metabolism (229) 229
protein-tyrosine kinases - antagonists & inhibitors (229) 229
endocrinology & metabolism (228) 228
science & technology - other topics (222) 222
cancer (218) 218
rna, messenger - metabolism (217) 217
multidisciplinary sciences (210) 210
protein binding (209) 209
signal transduction - physiology (206) 206
drug synergism (205) 205
cell cycle (195) 195
cells (195) 195
mitochondria (192) 192
tumors (191) 191
calcium (189) 189
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6822) 6822
Japanese (87) 87
Chinese (39) 39
Russian (20) 20
French (12) 12
German (11) 11
Portuguese (5) 5
Korean (4) 4
Spanish (2) 2
Ukrainian (2) 2
Danish (1) 1
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
by Stone, Richard M and DeAngelo, Daniel J and Klimek, Virginia and Galinsky, Ilene and Estey, Eli and Nimer, Stephen D and Grandin, Wilson and Lebwohl, David and Wang, Yanfeng and Cohen, Pamela and Fox, Edward A and Neuberg, Donna and Clark, Jennifer and Gilliland, D. Gary and Griffin, James D
Blood, ISSN 0006-4971, 01/2005, Volume 105, Issue 1, pp. 54 - 60
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Humans | Middle Aged | fms-Like Tyrosine Kinase 3 | Male | Staurosporine - analogs & derivatives | Staurosporine - pharmacokinetics | Phosphotyrosine - metabolism | Leukemia, Myeloid, Acute - enzymology | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Bone Marrow - drug effects | Proto-Oncogene Proteins - metabolism | Leukemia, Myeloid, Acute - pathology | Staurosporine - adverse effects | Staurosporine - blood | Proto-Oncogene Proteins - genetics | Enzyme Activation - drug effects | Mutation - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Blood Cell Count | Receptor Protein-Tyrosine Kinases - genetics | Staurosporine - therapeutic use | Bone Marrow - pathology | Aged | Enzyme Activation - genetics | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
by Thomas Fischer and Richard M. Stone and Daniel J. DeAngelo and Ilene Galinsky and Elihu Estey and Carlo Lanza and Edward Fox and Gerhard Ehninger and Eric J. Feldman and Gary J. Schiller and Virginia M. Klimek and Stephen D. Nimer and D. Gary Gilliland and Catherine Dutreix and Alice Huntsman-Labed and Jodi Virkus and Francis J. Giles
Journal of clinical oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 28, pp. 4339 - 4345
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Administration, Oral | Humans | Staurosporine - adverse effects | Male | Staurosporine - analogs & derivatives | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Myelodysplastic Syndromes - enzymology | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Receptor Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Staurosporine - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Myelodysplastic Syndromes - genetics | Mutation | Myelodysplastic Syndromes - drug therapy | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Index Medicus | Hema7 | ORIGINAL REPORTS | Bios3
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
by Stone, Richard M and Mandrekar, Sumithra J and Sanford, Ben L and Laumann, Kristina and Geyer, Susan and Bloomfield, Clara D and Thiede, Christian and Prior, Thomas W and Döhner, Hartmut and Döhner, Konstanze and Marcucci, Guido and Lo-Coco, Francesco and Klisovic, Rebecca B and Wei, Andrew and Sierra, Jorge and Sanz, Miguel A and Brandwein, Joseph M and de Witte, Theo and Niederwieser, Dietger and Appelbaum, Frederick R and Medeiros, Bruno C and Tallman, Martin S and Krauter, Jürgen and Schlenk, Richard F and Ganser, Arnold and Serve, Hubert and Ehninger, Gerhard and Amadori, Sergio and Larson, Richard A
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Midostaurin: First Global Approval
by Kim, Esther S
Drugs (New York, N.Y.), ISSN 0012-6667, 07/2017, Volume 77, Issue 11, pp. 1251 - 1259
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Leukemia, Mast-Cell - drug therapy | Mastocytosis, Systemic - drug therapy | United States | Humans | Middle Aged | Staurosporine - adverse effects | Staurosporine - analogs & derivatives | Clinical Trials as Topic | Drug Approval | Staurosporine - pharmacokinetics | Young Adult | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | United States Food and Drug Administration | Staurosporine - administration & dosage | Tyrosine | Drugs | Mastocytosis | Hematology | Transplants & implants | Leukemia | Diagnostic tests | Multiple myeloma | FDA approval | Kinases | Lymphoma | Chemotherapy | Cytarabine | Daunorubicin | Consolidation | Metabolites | Medical prognosis | Stem cells | Flt3 protein | Adults | Mutation | Protein-tyrosine kinase | Tumors
Journal Article
Details down arrow
5. Full Text Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
by Gotlib, Jason and Kluin-Nelemans, Hanneke C and George, Tracy I and Akin, Cem and Sotlar, Karl and Hermine, Olivier and Awan, Farrukh T and Hexner, Elizabeth and Mauro, Michael J and Sternberg, David W and Villeneuve, Matthieu and Huntsman Labed, Alice and Stanek, Eric J and Hartmann, Karin and Horny, Hans-Peter and Valent, Peter and Reiter, Andreas
The New England journal of medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2530 - 2541
MAST-CELL DISEASE | INTERFERON-ALPHA | THERAPY | RESPONSE CRITERIA | KIT MUTATION | D816V | ADULTS | KINASE INHIBITOR PKC412 | INTERNATIONAL WORKING GROUP | CLADRIBINE | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Leukemia, Mast-Cell - drug therapy | Multivariate Analysis | Mastocytosis, Systemic - drug therapy | Humans | Middle Aged | Staurosporine - adverse effects | Male | Staurosporine - analogs & derivatives | Treatment Outcome | Antineoplastic Agents - therapeutic use | Leukemia, Mast-Cell - mortality | Mastocytosis, Systemic - mortality | Antineoplastic Agents - adverse effects | Staurosporine - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Thrombocytopenia | Mastocytosis | Inhibitor drugs | Cell survival | Leukemia | Diarrhea | Nausea | FDA approval | Patients | Pathology | Vomiting | Medical prognosis | Tryptase | Bone marrow | Neutropenia | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
by Ma, Cynthia X and Cai, Shirong and Li, Shunqiang and Ryan, Christine E and Guo, Zhanfang and Schaiff, W. Timothy and Lin, Li and Hoog, Jeremy and Goiffon, Reece J and Prat, Aleix and Aft, Rebecca L and Ellis, Matthew J and Piwnica-Worms, Helen
The Journal of clinical investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1541 - 1552
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Receptors, Progesterone - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - analogs & derivatives | Thiophenes - pharmacology | Tumor Suppressor Protein p53 - deficiency | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Protein Kinase Inhibitors - administration & dosage | Urea - therapeutic use | Mice, Inbred NOD | Mice | DNA Damage | Cell Cycle - drug effects | Genes, cdc | Staurosporine - pharmacology | Urea - pharmacology | Staurosporine - administration & dosage | Neoplasm Proteins - physiology | Staurosporine - analogs & derivatives | Cell Line, Tumor - transplantation | Receptors, Estrogen - analysis | Thiophenes - administration & dosage | Molecular Targeted Therapy | Genes, p53 | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Cell Line, Tumor - metabolism | Urea - administration & dosage | Protein Kinases - drug effects | Receptors, Estrogen - genetics | Camptothecin - therapeutic use | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Protein Kinases - physiology | Checkpoint Kinase 1 | Neoplasm Proteins - analysis | Protein Kinase Inhibitors - pharmacology | Breast cancer | Genetic aspects | Research | Gene mutations | Health aspects | DNA damage | Index Medicus | Abridged Index Medicus | Estrogen | Càncer de mama | Ratolins (Animals de laboratori) | Apoptosi | Receptors d'hormones | Hormone receptors | Chemotherapy | Mice (Laboratory animals) | Progesterone | Quimioteràpia | Progesterona | Estrògens | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: Insights from human absorption, metabolism, and excretion studies of a BDDCS II drug
by He, Handan and Tran, Phi and Gu, Helen and Tedesco, Vivienne and Zhang, Jin and Lin, Wen and Gatlik, Ewa and Klein, Kai and Heimbach, Tycho
Drug metabolism and disposition, ISSN 0090-9556, 05/2017, Volume 45, Issue 5, pp. 540 - 555
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Protein Kinase Inhibitors - pharmacokinetics | Humans | Leukemia, Myeloid, Acute - metabolism | Middle Aged | Rats | Staurosporine - blood | Male | Staurosporine - analogs & derivatives | Leukemia, Myeloid, Acute - blood | Staurosporine - pharmacokinetics | Protein Kinase Inhibitors - blood | Young Adult | Animals | Staurosporine - urine | Mass Spectrometry | Dogs | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text GW28-e0855 The effect of bisdemethoxycurcumin on myocardial apoptosis induced by staurosporine
by Li, Xing and Wang, XiaoMing
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 16, pp. C182 - C182
Apoptosis | Cardiomyocytes | Staurosporine | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
by Strati, Paolo and Kantarjian, Hagop and Ravandi, Farhad and Nazha, Aziz and Borthakur, Gautam and Daver, Naval and Kadia, Tapan and Estrov, Zeev and Garcia‐Manero, Guillermo and Konopleva, Marina and Rajkhowa, Trivikram and Durand, Menda and Andreeff, Michael and Levis, Mark and Cortes, Jorge
American journal of hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Life Sciences & Biomedicine | Hematology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Azacitidine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Myelodysplastic Syndromes - enzymology | Dose-Response Relationship, Drug | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Drug Administration Schedule | Staurosporine - adverse effects | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Staurosporine - therapeutic use | Myelodysplastic Syndromes - mortality | Aged | Mutation | Azacitidine - therapeutic use | Staurosporine - administration & dosage | Index Medicus | AML | AZA | midostaurin | MDS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
by Yun, Cai-Hong and Boggon, Titus J and Li, Yiqun and Woo, Michele S and Greulich, Heidi and Meyerson, Matthew and Eck, Michael J
Cancer cell, ISSN 1535-6108, 2007, Volume 11, Issue 3, pp. 217 - 227
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Protein Structure, Tertiary | ErbB Receptors - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | ErbB Receptors - genetics | Models, Molecular | Crystallography, X-Ray | Staurosporine - analogs & derivatives | Antineoplastic Agents - chemistry | Purines - chemistry | ErbB Receptors - chemistry | Protein Conformation | Enzyme Activation | Lapatinib | Mutation | Gefitinib | Binding Sites | Quinazolines - chemistry | Staurosporine - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
by Wei, Andrew H and Tiong, Ing S
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 23, pp. 2469 - 2474
Life Sciences & Biomedicine | Hematology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Triazines - therapeutic use | Humans | Leukemia, Myeloid, Acute - metabolism | Staurosporine - analogs & derivatives | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | fms-Like Tyrosine Kinase 3 - genetics | Aminopyridines - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Daunorubicin - administration & dosage | Triazines - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Clinical Trials as Topic | Sulfonamides - pharmacology | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Sulfonamides - therapeutic use | Staurosporine - therapeutic use | Aminopyridines - pharmacology | Sialic Acid Binding Ig-like Lectin 3 - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Liposomes | Mutation | Aminoglycosides - pharmacology | Staurosporine - pharmacology | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights